Omada Health, Inc. OMDA
- Market cap
- $1.2B
- P/E
- 281×
Follow OMDA
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 14.14 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 28.40 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | 916 |
Employees
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | 123 | 170 | 260 |
Revenue
|
|||
| — | — | — | — | — | — | — | 56.99% | 60.59% | 65.69% |
Gross Margin
|
|||
| — | — | — | — | — | — | — | (68) | (47) | (13) |
EBT
|
|||
| — | — | — | — | — | — | — | (54.98%) | (27.76%) | (4.91%) |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (68) | (47) | (13) |
Net Income
|
|||
| — | — | — | — | — | — | — | 7 | 8 | 9 |
Depreciation
|
|||
| — | — | — | — | — | — | — | 17.32 | 21.99 | 7.10 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (9.52) | (6.10) | (0.35) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (7.01) | (4.43) | 0.50 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | (0.41) | (0.50) | (0.16) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (7.43) | (4.93) | 0.34 |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (49.79) | 6.27 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 7 | 8 | 37 |
Shares
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 2.22 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 2.52 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 1.48 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | (2.58) | (2.58) | 31.09 |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (50) | (34) | 18 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | (3) | (4) | (6) |
Capex
|
|||
| — | — | — | — | — | — | — | (53) | (38) | 12 |
FCF
|
|||
| — | — | — | — | — | — | — | — | 59 | 197 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 30 | — |
Total Debt
|
|||
| — | — | — | — | — | — | — | — | (47) | (222) |
Net Debt
|
|||
| — | — | — | — | — | — | — | 0 | (384) | 230 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | (62.48%) | (5.60%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | (97.89%) |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 16.52% |
ROE
|
|||
Omada Health, Inc. peers in Health Information Services
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GDRX GoodRx Holdings, Inc. | $1.2B | 62.5× | Compare |
| TDOC Teladoc Health, Inc. | $1.1B | 0.0× | Compare |
| CERT Certara, Inc. | $1.4B | 0.0× | Compare |
| OMCL Omnicell, Inc. | $1.5B | 39.5× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HSTM HealthStream, Inc. | $883.3M | 40.5× | Compare |
| SOPH SOPHiA GENETICS SA | $703.2M | 0.0× | Compare |
| SDGR Schrodinger, Inc. | $2.2B | 0.0× | Compare |
| MDRX Veradigm Inc. | $654.5M | 0.0× | Compare |
Omada Health, Inc. (OMDA) key facts
- Omada Health, Inc. (OMDA) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
- Omada Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $260.2 million, up 53.2% from fiscal 2024.
- As of September 25, 2026, OMDA traded at $19.66, a market capitalization of $1.2 billion.
- Return on equity was 16.5% and debt-to-equity 0.00.
Omada Health, Inc. (OMDA) Latest News
10 Sep
Omada Health will present updated long-term financial targets at its first Investor Day. Updated financial targets may shift investor views on growth trajectory without immediate operational changes.
9 Sep
Independent model projects up to $11,142 gross medical cost savings per member over five years from Omada Health GLP-1 program. Cost savings estimates for Omada GLP-1 program can drive higher adoption, revenue growth and stronger market positioning.
13 Aug
Omada Health (OMDA) held its Q2 2026 earnings call to discuss financial results and business updates. Earnings call reveals quarterly performance and guidance that can shift near-term investor sentiment and valuation.
11 Aug
Omada Health posts record Q2 results as GLP-1 demand drives its growth strategy. Record Q2 results tied to GLP-1 demand signal major positive shift in revenue trajectory and competitive positioning.
9 Aug
Omada Health (OMDA) may be 4% undervalued after posting record earnings that reset the valuation debate. Record earnings trigger a valuation reassessment that can moderately shift near-term investor sentiment and share price.
7 Aug
Omada Health Inc reported record revenue and profitability for Q2 2026. Record revenue and profitability directly strengthen financial trajectory and investor outlook.
Omada Health reported Q2 earnings with key metrics compared against analyst estimates. Q2 metrics versus estimates detail financial performance that may affect stock sentiment without major strategic shifts.
Omada Health held its Q2 earnings call and presented financial results along with operational updates. Q2 earnings results typically offer moderate insight into financial health and can shift near-term investor views.
6 Aug
Omada Health released second quarter 2026 financial results and announced a chief executive officer transition. Earnings release paired with CEO transition signals major strategic and performance implications for the company.
Omada Health, Inc. (OMDA) posted Q2 earnings and revenues above analyst estimates. Beating quarterly estimates typically produces moderate short-term stock gains without altering long-term company trajectory.
17 Jul
Omada Health (OMDA), an Eli Lilly partner, surges 118% in three months and is named IPO stock of the week. Eli Lilly partnership plus 118% stock gain point to major positive shifts in Omada's trajectory and sentiment.
8 May
Omada Health (OMDA) released Q1 2026 earnings call transcript detailing financial results, management discussion, and future outlook. Quarterly earnings transcripts reveal financial performance, guidance, and strategic updates that significantly influence stock price and investor sentiment.
Omada Health, Inc. (OMDA) conducted its Q1 2026 earnings call covering financial results, operational updates, and forward guidance. Earnings call delivers core financial metrics and strategy details that directly shape valuation and investor outlook.
Omada Health, Inc. (OMDA) released Q1 earnings call highlights detailing financial results, operational updates, and future guidance. Q1 earnings call highlights provide critical financial metrics, guidance, and strategic insights that significantly shape investor sentiment and market performance.
7 May
Omada Health, Inc. (OMDA) Q1 earnings compared to estimates, highlighting key metrics. Q1 earnings versus estimates significantly affect OMDA's financial trajectory and investor sentiment.
Omada Health (OMDA), Eli Lilly-linked recent IPO, reports first-quarter performance amid post-listing scrutiny. First-quarter results for a new Eli Lilly-tied IPO directly shape investor sentiment and stock trajectory.
Omada Health joins Lilly Employer Connect, expanding access pathways for GLP-1 care as patients increasingly seek comprehensive lifestyle support. Strategic partnership with Lilly broadens Omada's reach into the high-demand GLP-1 market, enhancing revenue potential and competitive positioning.
Omada Health, Inc. (OMDA) reported first quarter 2026 results. Quarterly earnings reports significantly affect financial performance metrics and investor sentiment.
17 Apr
New study finds Omada Health members using GLP-1 medications lose more fat, preserve muscle mass, and improve mental health compared to non-members. Study validates Omada's GLP-1 integration efficacy, boosting credibility and growth potential in high-demand weight management market.
25 Mar
Analyst expectations for Omada Health (OMDA) are resetting, shifting the company's investment story amid evolving market views. Resetting analyst expectations alters Omada's investment narrative, moderately influencing market sentiment and performance.
18 Mar
Omada Health, Inc. (OMDA) appoints Jakob H. Kraglund as CEO to accelerate global growth. CEO appointment signals major strategic push for global expansion, likely enhancing competitive positioning and investor sentiment.
16 Mar
Wall Street analysts predict Omada Health, Inc. (OMDA) stock could rally 59.53%, with detailed trading strategies outlined. Analyst consensus targets 59.53% upside for OMDA, likely boosting short-term investor sentiment and stock price moderately.
8 Mar
Omada Health (OMDA) stock jumped 14.4% after reporting its first GAAP profit and launching GLP-1 Flex, a flexible payment option for GLP-1 weight loss drugs, boosting access amid surging demand. First GAAP profit and GLP-1 Flex launch mark major financial milestone and strategic entry into booming GLP-1 market, driving sharp stock gains.
6 Mar
Omada Health, Inc. (OMDA) Q4 2025 earnings call summary highlights financial results, operational updates, and forward guidance for the digital health company. Q4 earnings call details financial performance and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.
5 Mar
Omada Health released Q4 earnings call highlights detailing financial performance, operational updates, and future outlook. Q4 earnings highlights disclose key financials, guidance, and strategy shifts that significantly affect investor sentiment and stock trajectory.
Omada Health, Inc. (OMDA) Q4 earnings key metrics compared to analyst estimates, highlighting performance across revenue, EPS, and other indicators. Q4 earnings comparison to estimates significantly influences investor sentiment and stock trajectory.
Omada Health launched GLP-1 Flex Care, a flexible program for employers to provide obesity care coverage including GLP-1 medications like Ozempic and Wegovy, featuring virtual coaching, dose tapering, and cost-management options to address access challenges. GLP-1 Flex Care launch taps into booming demand for obesity treatments, positioning Omada for revenue growth and enhanced competitive edge in digital health.
Omada Health, Inc. (OMDA) reported fourth quarter and full-year 2025 financial results. Quarterly and annual earnings disclosures significantly shape investor sentiment and stock trajectory.
19 Feb
Omada Health adds Cholesterol Care to its integrated platform, targeting cholesterol as a silent driver of cardiovascular risk to expand chronic care offerings. Launching Cholesterol Care expands Omada's platform into a key cardiovascular market, boosting revenue potential and competitive positioning.
17 Feb
Riverty Group selects Omada Health, Inc. (OMDA) to support identity governance at scale. Riverty Group's selection enables Omada to expand identity governance operations, moderately impacting revenue and competitive positioning.